Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Receivables (2020 - 2025)

Rapid Micro Biosystems' Receivables history spans 6 years, with the latest figure at $3.3 million for Q4 2025.

  • On a quarterly basis, Receivables fell 56.98% to $3.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.3 million, a 56.98% decrease, with the full-year FY2025 number at $3.3 million, down 56.98% from a year prior.
  • Receivables hit $3.3 million in Q4 2025 for Rapid Micro Biosystems, down from $5.6 million in the prior quarter.
  • Over the last five years, Receivables for RPID hit a ceiling of $7.6 million in Q4 2024 and a floor of $3.3 million in Q4 2025.
  • Historically, Receivables has averaged $5.0 million across 5 years, with a median of $5.0 million in 2024.
  • Biggest five-year swings in Receivables: soared 43.0% in 2023 and later crashed 56.98% in 2025.
  • Tracing RPID's Receivables over 5 years: stood at $5.3 million in 2021, then increased by 3.32% to $5.5 million in 2022, then grew by 2.75% to $5.6 million in 2023, then soared by 35.28% to $7.6 million in 2024, then tumbled by 56.98% to $3.3 million in 2025.
  • Business Quant data shows Receivables for RPID at $3.3 million in Q4 2025, $5.6 million in Q3 2025, and $6.1 million in Q2 2025.